Skip to main content
CRBP logo

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Track CRBP — free
$2.06 -0.38 (-15.40%) At close · Nov 20
Market Cap
$42.45M
Shares
20.61M
Volume · Nov 20 1.38M Avg daily vol (3M) 1.1M

Price & Indicators

 

Key stats

Close
$2.06
Fri 20 Nov
Open
$2.43
Fri 20 Nov
Average volume, 30 days
1.1M
shares a session
Short interest
3.2M
15.7% of shares · 3.5 days to cover
Day range
$2.01$2.48
Open $2.43 Close $2.06
52-week closing range
$2.06$12.15
Close $2.06 83.0% under the high
Short volume, last session
49%
Last earnings
Nov 15, 2026
Latest filing
10-Q · Nov 10
Price history
Jan 2020 to Nov 2026

Up next

Mar 5, 2027 Est · unconfirmed · in 15 wks
call held Mar 15, 2021

Latest documents

2026
Nov 18
Investor event
Tempo I trial in head and neck cancer targets accelerated approval

Corbus's Tempo I study in second-line oral pharyngeal cancer is designed for accelerated approval based on ORR, with final approval based on OS. The control arm is assumed at an ORR around about the 20%, and a BLA is expected around second half of 28. The CEO says key opinion leaders view an ORR north of 30% as desirable in second line and north of 50 in front line.

7 source passages
So you have this, the Tempo I phase three study, second line head and neck. So accelerated approval based on ORR. The study then continues, and finally is based, the final approval is based on OS. But the assumption of the second of the control arm is an ORR around about the 20%. So it looks like the BLA is expected around second half of 28. is anything north of 30% is clinically desirable and actionable. It's north of 50. Open the document at this passage
Nov 16
Current report 8-K
CRB-913 yields 5% weight loss at 60 mg

Corbus Pharmaceuticals Holdings, Inc. said CRB-913 produced significant mean weight loss at 20 mg, 40 mg and 60 mg; the highest dose achieved 5% after 12 weeks. Adverse-event discontinuation was 8.3%, with no serious or severe psychiatric adverse events.

Regulation FD disclosure, Other events
5 source passages
Corbus Pharmaceuticals Holdings, Inc. The trial included three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once daily, as well as a placebo cohort (randomization ratio of 1:1:1:1). The data demonstrated statistically significant and clinically meaningful weight loss at all three doses of CRB-913, with the highest dose of 60 mg achieving a mean weight loss of 5% at 12 weeks. The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is in line with published GLP-1 data. No serious or severe treatment-emergent psychiatric AEs were reported. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
CANYON-1 delivered 5% weight loss as net losses widened

Corbus Pharmaceuticals Holdings reported that CRB-913’s 60 mg dose achieved mean 5% weight loss at 12 weeks. Nine-month 2026 net loss widened to $95.8 million from $58.0 million, with $115.3 million in cash at September 30, 2026.

Net loss $37.75M Diluted EPS -$1.81
Read from the MD&A section
5 source passages
Corbus Pharmaceuticals Holdings, Inc. (the "Company," "Corbus," "we," "us," or "our") is a clinical-stage company focused on developing new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Our pipeline includes sutantatug envedotin (CRB-701), a next-generation antibody drug conjugate ("ADC") for the treatment of Nectin-4-expressing tumors and CRB-913, an orally delivered highly peripherally restricted cannabinoid type-1 ("CB1") inverse agonist for the treatment of obesity. The data demonstrated statistically significant and clinically meaningful weight loss at all three doses with the 60 mg dose achieving a mean weight loss of 5% at 12 weeks. Our net losses for the nine months ended September 30, 2026 and 2025, were approximately $95.8 million and $58.0 million, respectively. Based on current operating plans and assumptions regarding clinical timelines and other planned expenditures, we expect our cash, cash equivalents, and investments of approximately $115.3 million at September 30, 2026 will be sufficient to meet our operating and capital requirements through at least twelve months from the issuance of this Quarterly Report on Form 10-Q. Open the document at this passage
Nov 10
Current report 8-K
CRB-913 achieved 5% mean weight loss after 12 weeks

Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $37.8 million for Q3 2026 and held $115.3 million in cash, cash equivalents, and investments, expected to fund operations into 2028. CRB-913 achieved 5% mean weight loss after 12 weeks.

Financial results, Regulation FD disclosure
4 source passages
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, today provided a corporate update and reported financial results for the 2026 third quarter ended September 30, 2026. The Company reported a net loss of approximately $37.8 million, or a net loss per basic and diluted share of $1.81, for the three months ended September 30, 2026, compared to a net loss of approximately $23.3 million, or a net loss per basic and diluted share of $1.90, for the three months ended September 30, 2025. The Company had $115.3 million of cash, cash equivalents, and investments on hand as of September 30, 2026, which is expected to fund operations into 2028 based on current operating plans and planned expenditures. Reported topline data from the CANYON-1 Phase 1b obesity study of CRB-913 demonstrating mean weight loss of 5% after 12 weeks at 60 mg daily dose with no plateau observed and favorable safety and tolerability Open the document at this passage
Nov 9
Investor event
Oncology study progresses as obesity candidate shows weight loss

Corbus Pharmaceuticals launched a phase three registrational study in second line oral pharyngeal cancer and reported 5% weight loss in three months in a phase 1b obesity trial with about 250 patients.

4 source passages
I'm very excited to be welcoming our first company of the day, which is Corbus Pharmaceuticals. We have just launched its phase three registrational study in second line oral pharyngeal. It's in the clinic, as you know, and just completed a – technically, it's a phase 1b, but it's a pretty large one. It was a four-month in total, three months of dosing, once a day, double-blind placebo-controlled with about 250 patients. We saw 5% weight loss in three months, double-blind placebo-adjusted. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$116.31M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-184.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$115.34M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+69.3%
Year over year · more shares
Price change (1Y)
-82.4%
Trailing year
Short interest
15.7%
Latest settlement · 3.5 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −75%
below
Price vs 50-day avg −59%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −49%
trailing
6-month return −73%
trailing
YTD return −75%
this year
Relative strength −64%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+16% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.74% of shares out · ▲ +19.5% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
124 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Fair
Revenue growth +98%
Y/Y
EPS growth −60%
Y/Y
Free cash flow $-64.5M
Balance sheet $28.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 83%
annualized · 1-yr
Max drawdown −83%
past year
ATR 22.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−75% Bearish
Price vs 50-day avg
−59% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $5 › 200d $8 — 200d above 50d
Institutional flow Accumulating
+16% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
15.74% of shares out · ▲ +19.5% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
124 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $12
vs 200-day avg -75% vs 50-day avg -59%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and investments $115.3M as of September 30, 2026 —
net proceeds under the Open Market Sale Agreement $18.6M the three months ended September 30, 2026 filing —
research and development expenses recorded in U.K. and Australia subsidiaries 13% the three months ended September 30, 2026 filing —
shares of common stock sold under the Open Market Sale Agreement 1,932,621 the three months ended September 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CRBP
Corbus Pharmaceuticals Holdings, Inc.
this stock
$42.45M -74.7% +97.6% — 15.7%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
124
% held
85.5%
Net QoQ
+3.9M sh
Top holder
Cormorant Asset Managemen…
Held Float
View
Held by Funds
Fund positions
98
View
Short & Settlement
Short Interest Rising
Shares short
3.2M
Days to cover
3.5d
Change
+529.8K sh
View
Short Volume
Short vol %
49%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
231
Value
$1.0K
As of
Oct 20, 2026
View
Off-Exchange
Off-exchange %
47.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-78.5M
EPS diluted
$-5.90
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
30

Corbus's Tempo I study in second-line oral pharyngeal cancer is designed for accelerated approval based on ORR, with final approval based on OS. The control arm is assumed at an ORR around about the 20%, and a BLA is expected around second half of 28. The CEO says key opinion leaders view an ORR north of 30% as desirable in second line and north of 50 in front line.

View
Proposed Sales
Value
$121.0K
Shares
12.0K
Filed
Aug 7, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Corbus Pharmaceuticals presents P…
Published
Nov 16, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
CRBP -39.2% -49.1% -72.7% -51.2% -74.7%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -30.7% -39.9% -63.5% -42.5% -75.9%
Key facts CIK 1595097 CUSIP 21833P301 13F (30d) 129 filings 111 filers Visit website Investor relations